KALA BIO, Inc. (KALA) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Arlington, MA, 미국. 현재 CEO는 Avi Minkowitz.
KALA 을(를) 보유 IPO 날짜 2017-07-20, 38 명의 정규직 직원, 에 상장 NASDAQ Global Select, 시가총액 $4.2M.
Kala Bio, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based mucus penetrating particles with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Arlington, MA.
